JP2004527489A - フタル酸ヒドロキシプロピルメチルセルロースポリマーの固体分散物を含む医薬組成物 - Google Patents

フタル酸ヒドロキシプロピルメチルセルロースポリマーの固体分散物を含む医薬組成物 Download PDF

Info

Publication number
JP2004527489A
JP2004527489A JP2002567272A JP2002567272A JP2004527489A JP 2004527489 A JP2004527489 A JP 2004527489A JP 2002567272 A JP2002567272 A JP 2002567272A JP 2002567272 A JP2002567272 A JP 2002567272A JP 2004527489 A JP2004527489 A JP 2004527489A
Authority
JP
Japan
Prior art keywords
compound
polymer
pharmaceutical composition
solid dispersion
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002567272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004527489A5 (enExample
Inventor
ベイトマン，ニコラ
カヒル，ジュリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2004527489A publication Critical patent/JP2004527489A/ja
Publication of JP2004527489A5 publication Critical patent/JP2004527489A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2002567272A 2001-02-27 2002-02-25 フタル酸ヒドロキシプロピルメチルセルロースポリマーの固体分散物を含む医薬組成物 Pending JP2004527489A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0104752.1A GB0104752D0 (en) 2001-02-27 2001-02-27 Pharmaceutical compositions
PCT/SE2002/000327 WO2002067904A1 (en) 2001-02-27 2002-02-25 Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer

Publications (2)

Publication Number Publication Date
JP2004527489A true JP2004527489A (ja) 2004-09-09
JP2004527489A5 JP2004527489A5 (enExample) 2005-12-22

Family

ID=9909545

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002567272A Pending JP2004527489A (ja) 2001-02-27 2002-02-25 フタル酸ヒドロキシプロピルメチルセルロースポリマーの固体分散物を含む医薬組成物

Country Status (14)

Country Link
US (1) US20040138231A1 (enExample)
EP (1) EP1365746A1 (enExample)
JP (1) JP2004527489A (enExample)
KR (1) KR20040011469A (enExample)
CN (1) CN1533268A (enExample)
BR (1) BR0206960A (enExample)
CA (1) CA2435815A1 (enExample)
GB (1) GB0104752D0 (enExample)
IL (1) IL156830A0 (enExample)
MX (1) MXPA03006746A (enExample)
NO (1) NO20033782L (enExample)
NZ (1) NZ527080A (enExample)
WO (1) WO2002067904A1 (enExample)
ZA (1) ZA200305386B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2004105728A2 (en) * 2003-05-27 2004-12-09 Ranbaxy Laboratories Limited Solid dispersions of cefpodoxime proxetil and processes for their preparation
KR100531612B1 (ko) * 2003-08-12 2005-11-28 경동제약 주식회사 지속성 탐스로신 정제의 제조방법 및 그에 따른 지속성탐스로신 정제
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EP2278957A2 (en) * 2008-04-15 2011-02-02 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
EP2346495B2 (en) * 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
CN104188893A (zh) * 2014-08-18 2014-12-10 赵明亮 一种盐酸环丙沙星口服固体制剂及其制备工艺
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
WO2025078941A1 (en) * 2023-10-09 2025-04-17 Intas Pharmaceuticals Ltd. Pharmaceutical composition of pirtobrutinib

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57120518A (en) * 1981-01-19 1982-07-27 Tanabe Seiyaku Co Ltd Preparation of microcapsule
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
TW212139B (enExample) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
DE69428707T2 (de) * 1993-08-20 2002-07-11 Nippon Shinyaku Co., Ltd. Im magen verbleibende zubereitung, quellender formkörper und herstellungsverfahren
CN1133634C (zh) * 1998-05-02 2004-01-07 阿斯特拉曾尼卡有限公司 抑制因子Xa的杂环衍生物
JP5159012B2 (ja) * 1999-12-23 2013-03-06 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 不良溶解性の薬物に対する改良された医薬組成物

Also Published As

Publication number Publication date
ZA200305386B (en) 2004-10-11
NZ527080A (en) 2005-02-25
KR20040011469A (ko) 2004-02-05
GB0104752D0 (en) 2001-04-18
EP1365746A1 (en) 2003-12-03
US20040138231A1 (en) 2004-07-15
MXPA03006746A (es) 2003-10-24
NO20033782D0 (no) 2003-08-26
NO20033782L (no) 2003-08-26
WO2002067904A1 (en) 2002-09-06
CA2435815A1 (en) 2002-09-06
BR0206960A (pt) 2004-03-09
CN1533268A (zh) 2004-09-29
IL156830A0 (en) 2004-02-08

Similar Documents

Publication Publication Date Title
JP5775071B2 (ja) アピキサバンの製剤形
KR102593075B1 (ko) 셀렉시파그를 포함하는 약학 조성물
JP7425794B2 (ja) 置換されたインダンを含む固体分散体及び医薬組成物並びにそれの製造方法及び使用
CA2720851A1 (en) Oral pharmaceutical compositions in a molecular solid dispersion
WO2001095912A1 (fr) Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
TWI660746B (zh) 一種替格瑞洛固體分散體及其製備方法
CN105232488B (zh) 一种含有利伐沙班的固体药物组合物
EP3435985A1 (en) Granulate formulation of 5-methy!-1-pheny!-2(1h)-pyridone and method of making the same
US20210369620A1 (en) Solid dosage forms with high active agent loading
JPWO2008066102A1 (ja) 徐放性製剤
IL310203A (en) Pharmaceutical composition containing 2-{4n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide
EP2068835A2 (en) Imatinib compositions
US20040138231A1 (en) Pharmaceutical composition which comprise a solid dispersion of a hydroxypropyl-methylcellulose phthalate polymer
AU2023274142B2 (en) Crystal
KR20200088382A (ko) 방출 제어 제제
KR20220087443A (ko) 셀렉시파그를 포함하는 약제학적 조성물
CN105377240A (zh) 固体药物剂型
US20240293323A1 (en) Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
CN110193012B (zh) 一种氧代吡啶酰胺类衍生物的药物组合物及其制备方法
TW200817000A (en) New paediatric indications for direct thrombin inhibitors
EP1030664A1 (en) Pharmaceutical compositions containing zafirlukast
KR20090033825A (ko) 일라프라졸의 약제학적 조성물
KR101823071B1 (ko) 텔미사르탄-함유 정제의 제조방법
AU2002233882A1 (en) Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer
EP4552633A1 (en) Pharmaceutical compositions comprising amorphous solid solutions of rivaroxaban and copovidone and preparation methods thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081009

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090109

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090401